Composition comprising a culture solution of mesenchymal stem cells for the treatment of neural diseases
AssigneeMedipost Co., Ltd.
InventorsYoon-Sun Yang, Won II Oh, Jong Wook Chang, Ju Yeon Kim
Life of this patent
Estimating the term…
Abstract
Provided are a pharmaceutical composition for prevention and treatment of a neural disease including at least one selected from the group consisting of mesenchymal stem cells (MSCs), a culture solution of the MSCs, activin A, PF4, decorin, galectin 3, GDF15, glypican 3, MFRP, ICAM5, IGFBP7, PDGF-AA, SPARCL1, thrombospondin-1, WISP1, progranulin, IL-4, a factor inducing expression thereof, and any combination thereof, and a method therefor.
Claims13
A method of treating a neural disease selected from the group consisting of Alzheimer's disease and Parkinson's disease, the method comprising administering directly a pharmaceutical composition comprising, as an active ingredient, a culture solution of umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) into the brain of a subject in need of treating the neural disease,
- wherein the culture solution of UCB-MSCs is obtained by a process comprising co-culturing UCB-MSCs with amyloid-beta-treated neurons without direct contact between the UCB-MSCs and the amyloid beta-treated neurons, said UCB-MSCs and said amyloid beta-treated neurons being separated from each other by a porous membrane.
A method of treating a neural disease selected from the group consisting of Alzheimer's disease and Parkinson's disease, the method comprising administering directly a pharmaceutical composition comprising, as an active ingredient, co-cultured umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) into brain parenchyma or ventricle of a subject in need of treating the neural disease,
- wherein the co-cultured UCB-MSCs are obtained by a process comprising co-culturing UCB-MSCs with amyloid-beta-treated neurons without direct contact between the UCB-MSCs and the amyloid beta-treated neurons and the UCB-MSCs and the amyloid beta-treated neurons are separated by a porous membrane.
A method for reducing amyloid-beta plaques in neural tissues of a subject, comprising administering directly a pharmaceutical composition comprising, as an active ingredient, co-cultured umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) into brain parenchyma or ventricle of the subject,
- wherein the co-cultured UCB-MSCs are obtained by a process comprising co-culturing UCB-MSCs with amyloid-beta-treated neurons without direct contact between the UCB-MSCs and the amyloid beta-treated neurons and the UCB-MSCs and the amyloid beta-treated neurons are separated by a porous membrane.
A method for increasing an expression of neprilysin in neural tissues of a subject, comprising administering directly a pharmaceutical composition comprising, as an active ingredient, co-cultured umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) into brain parenchyma or ventricle of the subject,
- wherein the co-cultured UCB-MSCs are obtained by a process comprising co-culturing UCB-MSCs with amyloid-beta-treated neurons without direct contact between the UCB-MSCs and the amyloid beta-treated neurons and the UCB-MSCs and the amyloid beta-treated neurons are separated by a porous membrane.
Dependencies are inferred from the claim text.